ELYM
NASDAQEliem Therapeutics Inc
Latest news
25 items- SECSEC Form 8-K filed by Eliem Therapeutics Inc8-K - Climb Bio, Inc. (0001768446) (Filer)
- PREliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.Name change to "Climb Bio" marks the Company's transition and focus on developing treatments for immune-mediated diseases Climb Bio will begin trading on Nasdaq under the trading symbol "CLYM" effective October 3rd WELLESLEY, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), announced today that it will change its corporate name to Climb Bio, Inc. The new name and corporate brand reflect the Company's new mission to develop a pipeline focused on immune-mediated diseases, following its acquisition of Tenet Medicines, Inc. In conjunction with the corporate name change, the Company will begin trading under the new ticker symbol "CLYM" on the Nasdaq Global Mar
- INSIDERCHIEF ACCOUNTING OFFICER Pimblett Emily converted options into 5,000 shares and sold $9,741 worth of shares (1,191 units at $8.18), increasing direct ownership by 101% to 7,564 units (SEC Form 4)4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
- PREliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation SummitSEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024. Stifel 2024 Virtual Immunology and Inflammation SummitDate: Wednesday, September 18, 2024Format: 1x1 meetings About Eliem Therapeutics, Inc.Eliem Therapeutics is focused on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, immune thrombocyto
- SECSEC Form 8-K filed by Eliem Therapeutics Inc8-K - Eliem Therapeutics, Inc. (0001768446) (Filer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Kaplan Brett4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kaplan Brett3 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
- SECSEC Form 8-K filed by Eliem Therapeutics Inc8-K - Eliem Therapeutics, Inc. (0001768446) (Filer)
- PREliem Therapeutics Announces Additions to its Leadership TeamBrett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D. appointed Senior Vice President, Clinical Development SEATTLE and CAMBRIDGE, United Kingdom, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM), announced today the appointments of Brett Kaplan, M.D., as Chief Operating Officer, and Nishi Rampal, M.D., as Senior Vice President, Clinical Development. "I am delighted to announce the addition of Brett and Nishi to our executive team," said Dr. Aoife Brennan, CEO of Eliem Therapeutics. "Since completing the Tenet Medicines acquisition, we have worked diligently to build a best-in-class management team as we transition Eliem into a leading bio
- 13D/GAmendment: SEC Form SC 13D/A filed by Eliem Therapeutics IncSC 13D/A - Eliem Therapeutics, Inc. (0001768446) (Subject)
- 13D/GAmendment: SEC Form SC 13G/A filed by Eliem Therapeutics IncSC 13G/A - Eliem Therapeutics, Inc. (0001768446) (Subject)
- SECEliem Therapeutics Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Eliem Therapeutics, Inc. (0001768446) (Filer)
- SECSEC Form 10-Q filed by Eliem Therapeutics Inc10-Q - Eliem Therapeutics, Inc. (0001768446) (Filer)
- PREliem Therapeutics Reports Second Quarter Financial ResultsEliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred to as TNT119), pipeline expansion strategy and anticipated milestones Cash and cash equivalents of approximately $220 million expected to fund operations into 2027, to enable the potential attainment of key clinical and development milestones for budoprutug SEATTLE and CAMBRIDGE, United Kingdom, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (NASDAQ:ELYM) ("Eliem" or the "Company"), today reported financial results for the quarter ended June 30, 2024 and provided a business
- SECSEC Form EFFECT filed by Eliem Therapeutics IncEFFECT - Eliem Therapeutics, Inc. (0001768446) (Filer)
- INSIDEREVP, R&D AND CSO Morisset Valerie sold $988,495 worth of shares (129,206 units at $7.65), decreasing direct ownership by 80% to 31,317 units (SEC Form 4)4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
- SECSEC Form 424B3 filed by Eliem Therapeutics Inc424B3 - Eliem Therapeutics, Inc. (0001768446) (Filer)
- NEWSIQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On MondayU.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday. Shares of IQVIA Holdings Inc. (NYSE:IQV) rose sharply during Monday's session after the company released better-than-expected second-quarter financial results and raised its 2024 guidance. IQVIA reported a second adjusted EPS of $2.64, up from $2.43, beating the consensus of $2.57. Provider of advanced analytics reported sales of $3.81 billion, beating the consensus of $3.79 billion, according to data from Benzinga Pro. IQVIA Holdings shares jumped 7.4% to $241.07 on Monday. Here are some other big stocks recording gains in today’s session. Tellurian Inc. (NASDAQ:TELL) shares surged 64.5% to
- INSIDEREVP, R&D AND CSO Morisset Valerie sold $289,492 worth of shares (41,783 units at $6.93), decreasing direct ownership by 21% to 160,523 units (SEC Form 4)4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
- INSIDEREVP, R&D AND CSO Morisset Valerie sold $356,500 worth of shares (50,000 units at $7.13), decreasing direct ownership by 20% to 202,306 units (SEC Form 4)4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
- INSIDEREVP, R&D AND CSO Morisset Valerie sold $650,563 worth of shares (92,377 units at $7.04), decreasing direct ownership by 27% to 252,306 units (SEC Form 4)4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
- NEWSEliem Therapeutics Files Prospectus Relates To Resale From Time To Time Of Up To 36.8M Shares Of Common Stock By Selling Stockholders- SEC Filing
- SECSEC Form S-3 filed by Eliem Therapeutics IncS-3 - Eliem Therapeutics, Inc. (0001768446) (Filer)
- INSIDEREVP, R&D AND CSO Morisset Valerie sold $736,500 worth of shares (105,931 units at $6.95), decreasing direct ownership by 24% to 344,683 units (SEC Form 4)4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
- INSIDEREVP, R&D AND CSO Morisset Valerie sold $87,135 worth of shares (12,342 units at $7.06), decreasing direct ownership by 3% to 450,614 units (SEC Form 4)4 - Eliem Therapeutics, Inc. (0001768446) (Issuer)
ELYM FAQ
7 questionsWhat does Eliem Therapeutics Inc do?
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain and ETX-155 for major depressive disorder, perimenopausal depression, and focal onset seizures. The company also develops preclinical pipeline programs, such as Kv7 Program for pain epilepsy; and Anxiolytic for the treatment of generalized anxiety. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in...Where does ELYM stock trade?
Eliem Therapeutics Inc (ELYM) is listed on NASDAQ.What sector and industry is ELYM in?
Eliem Therapeutics Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Eliem Therapeutics Inc go public?
Eliem Therapeutics Inc (ELYM) completed its IPO in 2021.What are analysts saying about ELYM?
Eliem Therapeutics Inc has had 3 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $3200.00 price target on 2021-09-07. Recent price targets range from $3200.00 to $3500.00.What companies are similar to ELYM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ELYM side-by-side with any of them on Quantisnow.How can I track ELYM on Quantisnow?
Quantisnow aggregates Eliem Therapeutics Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ELYM to receive live email and push alerts on every new disclosure.